Merck
33
15M
14
0.09
6
3
- Areas of investment
Summary
Merck is the famous Corporate Investor, which was founded in 1891. The leading representative office of defined Corporate Investor is situated in the Kenilworth. The venture was found in North America in United States.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Merck, startups are often financed by Tichenor Ventures, Skyline Ventures, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are ARCH Venture Partners, Lilly Asia Ventures, Bill & Melinda Gates Foundation. In the next rounds fund is usually obtained by Lilly Asia Ventures, ARCH Venture Partners, Temasek Holdings.
Among the most popular fund investment industries, there are Health Diagnostics, Medical. Among the most popular portfolio startups of the fund, we may highlight Moderna Therapeutics, NGM Biopharmaceuticals, GenomeDx Biosciences. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 2 of the founder, the probability for it to get the investment is little.
The average startup value when the investment from Merck is 500 millions - 1 billion dollars. The top activity for fund was in 2016. The increased amount of exits for fund were in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this Corporate Investor is 2 percentage points less often commits exit comparing to other companies. This Merck works on 6 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in less than 2 investment rounds annually.
The current fund was established by George W. Merck. We also calculated 2 valuable employees in our database.
Investments analytics
Analytics
- Total investments
- 33
- Lead investments
- 6
- Exits
- 3
- Rounds per year
- 0.09
- Investments by industry
- Biotechnology (10)
- Pharmaceutical (4)
- Medical (4)
- Health Care (3)
- Life Science (3) Show 28 more
- Investments by region
-
- United States (9)
- United Kingdom (2)
- China (1)
- Germany (1)
- Netherlands (1)
- Peak activity year
- 2018
- Number of Unicorns
- 2
- Number of Decacorns
- 2
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Avg. valuation at time of investment
- 557M
- Group Appearance index
- 0.79
- Avg. company exit year
- 4
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Aktis Oncology | 25 Aug 2022 | Biotechnology, Life Science | Early Stage Venture | 84M | United States, Massachusetts, Boston |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.